Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
Department of Respiratory Diseases, University Hospital Sassari (AOU), Sassari, Italy.
Respir Res. 2018 Mar 27;19(1):51. doi: 10.1186/s12931-018-0754-7.
Idiopathic pulmonary fibrosis (IPF), a fatal lung disease of unknown origin, is characterized by chronic and progressive fibrosing interstitial pneumonia which progressively impairs lung function. Oxidative stress is one of the main pathogenic pathways in IPF. The aim of this systematic review was to describe the type of markers of oxidative stress identified in different biological specimens and the effects of antioxidant therapies in patients with IPF.
We conducted a systematic search of publications listed in electronic databases (Pubmed, Web of Science, Scopus and Google Scholar) from inception to October 2017. Two investigators independently reviewed all identified articles to determine eligibility.
After a substantial proportion of the initially identified articles (n = 554) was excluded because they were duplicates, abstracts, irrelevant, or did not meet the selection criteria, we identified 30 studies. In each study, we critically appraised the type, site (systemic vs. local, e.g. breath, sputum, expired breath condensate, epithelial lining fluid, bronchoalveolar lavage, and lung tissue specimens), and method used for measuring the identified oxidative stress biomarkers. Furthermore, the current knowledge on antioxidant therapies in IPF was summarized.
A number of markers of oxidative stress, with individual advantages and limitations, have been described in patients with IPF. Nevertheless, trials of antioxidant treatments have been unable to demonstrate consistent benefits, barring recent pharmacogenomics data suggesting different results in specific genotype subgroups of patients with IPF.
特发性肺纤维化（IPF）是一种病因不明的致命肺部疾病，其特征为慢性、进行性纤维性间质性肺炎，逐渐损害肺功能。氧化应激是 IPF 的主要发病机制之一。本系统评价旨在描述不同生物标本中鉴定出的氧化应激标志物的类型，以及抗氧化治疗对 IPF 患者的影响。
我们对电子数据库（Pubmed、Web of Science、Scopus 和 Google Scholar）中的出版物进行了系统检索，检索时间从建库至 2017 年 10 月。两名研究者独立审查所有确定的文章，以确定其是否符合纳入标准。
在最初确定的大量文章（n=554）中，有相当一部分被排除，因为它们是重复的、摘要、不相关的，或者不符合选择标准，我们确定了 30 项研究。在每一项研究中，我们都批判性地评估了所鉴定的氧化应激生物标志物的类型、部位（全身性与局部，如呼吸、痰、呼出气冷凝物、上皮衬液、支气管肺泡灌洗和肺组织标本）和测量方法。此外，还总结了目前关于 IPF 抗氧化治疗的知识。
在 IPF 患者中已经描述了许多氧化应激标志物，它们具有各自的优缺点。然而，抗氧化治疗的试验未能证明一致的益处，除了最近的药物基因组学数据表明，在 IPF 患者的特定基因型亚组中可能有不同的结果。
